OTC Deficiency Treatment Market Primed to Grow at a Robust Pace Due...

Ajouter une nouvelle offre d'emploi Autre

2024-08-21 11:58:14 -

OTC Deficiency Treatment Market Primed to Grow at a Robust Pace Due to Rising Prevalence

The ornithine transcarbamylase (OTC) deficiency treatment market is majorly driven by the increasing prevalence of urea cycle disorders. Urea cycle disorders are genetic conditions that cause a buildup of ammonia in the blood. Symptoms range from mild to severe, depending on the specific genetic changes and can affect any organ system. Some key symptoms include vomiting, seizures, intellectual...

0 Commentaires 0 Parts 130 Vue 0 Aperçu